|
OTLK | Outlook Therapeutics, Inc. |
|
|
OTLK | Outlook Therapeutics, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ -0.07 |
| Leverage | 277.68% |
| Market Cap | $ 1.3B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -93.5m |
| Margin | 3032.50% |
Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey.